To see the issue content and the abstract you do not have to login
Please login to download the full articles

Lost password?      Click here!

If you do not have a subscription to Rhinology please consider to take one.
Click here to become a member of the European Rhinologic Society and a subscriber to the journal `RHINOLOGY`, beginning 2019. Subscription including membership fee: Euro 139.-

If you only want to buy this paper please click here
The price of the paper is 25 euro.

Topical nasal decongestant oxymetazoline (0.05%) provides relief of nasal symptoms for 12 hours

Volume: 56 - Issue: 4

Firstpage: 343 - Lastpage: 350

H.M. Druce - D.L. Ramsey - S. Karnati - A.N. Carr

BACKGROUND: Nasal congestion, often referred to as stuffy nose or blocked nose is one of the most prevalent and bothersome symptoms of an upper respiratory tract infection. Oxymetazoline, a widely used intranasal decongestant, offers fast symptom relief, but little is known about the duration of effect.
METHODOLOGY: The results of 2 randomized, double-blind, vehicle-controlled, single-dose, parallel, clinical studies (Study 1, n=67; Study 2, n=61) in which the efficacy of an oxymetazoline (0.05% Oxy) nasal spray in patients with acute coryzal rhinitis was assessed over a 12-hour time-period. Data were collected on both subjective relief of nasal congestion (6-point nasal congestion scale) and objective measures of nasal patency (anterior rhinomanometry) in both studies.
RESULTS: A pooled study analysis showed statistically significant changes from baseline in subjective nasal congestion for 0.05% oxymetazoline and vehicle at each hourly time-point from Hour 1 through Hour 12 (marginally significant at Hour 11). An objective measure of nasal flow was statistically significant at each time-point up to 12 hours. Adverse events on either treatment were infrequent. The number of subjects who achieved an improvement in subjective nasal congestion scores of at least 1.0 was significantly higher in the Oxy group vs. vehicle at all hourly time-points on a 6-point nasal congestion scale.
CONCLUSIONS: This study shows for the first time, that oxymetazoline provides both statistically significant and clinically meaningful relief of nasal congestion and improves nasal airflow for up to 12 hours following a single dose.

H.M. Druce - D.L. Ramsey - S. Karnati - A.N. Carr - Topical nasal decongestant oxymetazoline (0.05%) provides relief of nasal symptoms for 12 hours
Rhinology 56-4: 343-350, 2018